ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. BioScience Health Innovations's annualizedNet Income for the quarter that ended in Mar. 2026 was $-0.92 Mil.
BioScience Health Innovations's average Total Assets over the quarter that ended in Mar. 2026 was $2.02 Mil. Therefore, BioScience Health Innovations's annualized ROA % for the quarter that ended in Mar. 2026 was -45.58%.
The historical rank and industry rank for BioScience Health Innovations's ROA % or its related term are showing as below:
BHIC'
s ROA % Range Over the Past 10 Years
Min: -754.55 Med: -131.08 Max: 49.75
Current: -0.78
During the past 7 years, BioScience Health Innovations's highest ROA % was 49.75%. The lowest was -754.55%. And the median was -131.08%.
BHIC's ROA % is ranked worse than 64.58% of 686
companies
in the Healthcare Providers & Services industry
Industry Median: 1.75
vs BHIC: -0.78
BioScience Health Innovations (OTCPK:BHIC) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
BioScience Health Innovations ROA % Related Terms
BioScience Health Innovations ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's ROA % distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
BioScience Health Innovations (BHIC) has a ROA % of -45.58% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on BioScience Health Innovations and its competitors. According to the industry distribution chart, BioScience Health Innovations ranks #443 out of 686 companies in the Healthcare Providers & Services industry, placing it in the top 64.6%.
Is BioScience Health Innovations' ROA % too high?
BioScience Health Innovations' current ROA % is -45.58%. Based on the distribution chart, BioScience Health Innovations ranks #443 out of 686 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, BioScience Health Innovations has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' ROA % compare to PETS and SHFH?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #443 out of 686 companies for ROA %. This places BioScience Health Innovations in the lower half of its industry. The industry median ROA % is 1.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.75, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current ROA % is -45.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.35 — trading 97.4% below its estimated fair value. The current ROA % is -45.58%. BioScience Health Innovations' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current ROA % is -45.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.35 is trading 97.4% below its estimated GF Value™ of $164.84.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
ROA %: -45.58%
GF Value™: $164.84 vs. price of $4.35 (97.4% below fair value)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Business Description
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
45GF Score
Get the complete analysis for BHIC
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
